Upfront use of these drugs in induction therapy has significantly increased the rate and depth of responses that have translated into longer remission and survival. Outcomes of patients with MM have improved significantly due to the advent of several novel drugs. Autologous stem cell transplantation (auto-SCT) has been the standard of care in eligible newly diagnosed multiple myeloma (MM) patients.
